BRCA1 5083del19 mutant allele selectively up-regulates periostin expression in vitro and in vivo

Clinical Cancer Research

Volumn 14, Issue 21, 2008, Pages 6797-6803

  Quaresima, Barbara ^a   Romeo, Francesco ^a   Faniello, Maria C ^a   Di Sanzo, Maddalena ^a   Liu, Chang Gong ^c   Lavecchia, Annamaria ^b   Taccioli, Cristian ^c   Gaudio, Eugenio ^a   Baudi, Francesco ^a   Trapasso, Francesco ^a   Croce, Carlo M ^c   Cuda, Giovanni ^a   Costanzo, Francesco ^a  

^a UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

^b PUGLIESE CIACCIO HOSPITAL   (Italy)

^c OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; TRANSCRIPTION FACTOR RUNX2; CELL ADHESION MOLECULE; POSTN PROTEIN, HUMAN; UNCLASSIFIED DRUG;

ALLELE; ARTICLE; BREAST CANCER; CONTROLLED STUDY; FAMILIAL CANCER; GENE DELETION; GENE EXPRESSION; GENE MUTATION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MICROARRAY ANALYSIS; PRIORITY JOURNAL; PROTEIN DOMAIN; SERODIAGNOSIS; UPREGULATION; BREAST TUMOR; DNA MICROARRAY; FEMALE; FOUNDER EFFECT; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; HELA CELL; METABOLISM; MUTATION; TUMOR CELL LINE; TUMOR SUPPRESSOR GENE;

BREAST NEOPLASMS; CELL ADHESION MOLECULES; CELL LINE, TUMOR; FEMALE; FOUNDER EFFECT; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, BRCA1; HELA CELLS; HUMANS; IMMUNOHISTOCHEMISTRY; MUTATION; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; UP-REGULATION;

EID: 58149265466     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-5208     Document Type: Article

References (53)

1. Miki Y, Swensen J, Shattuck-Eidens D, et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 1994;266:66-71.
2. Antoniou A, Pharoah PD, Narod S, et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 2003;72:1117-30.
3. FitzGerald MG, MacDonald DJ, Krainer M, et al. Germ-line BRCA1 mutations in Jewish and non-Jewish women with early onset breast cancer. N Engl J Med 1996;334:143-9.
4. Yang Q, Sakurai T, Mori I, et al. Prognostic significance of BRCA1 expression in Japanese sporadic breast carcinomas. Cancer 2001;92:54-60.
5. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100:57-70.
6. Lal A, Lash AE, Altschul SF, et al. A public database for gene expression in human cancers. Cancer Res 1999;59:5403-7.
7. Velculescu VE, Vogelstein B, Kinzler KW. Analysing uncharted transcriptomes with SAGE. Trends Genet 2000;16:423-5.
8. Velculescu VE, Zhang L, Vogelstein B, Kinzler KW. Serial analysis of gene expression. Science 1995;270:484-7.
9. West M, Blanchette C, Dressman H, et al. Predicting the clinical status of human breast cancer by using gene expression profiles. Proc Natl Acad Sci U S A 2001;98:11462-7.
10. Zhang L, Zhou W, Velculescu VE, et al. Gene expression profiles in normal and cancer cells. Science 1997;276:1268-72.
11. Perou CM, Jeffrey SS, van de Rijn M, et al. Distinctive gene expression patterns in human mammary epithelial cells and breast cancers. Proc Natl Acad Sci U S A 1999;96:9212-7.
12. Perou CM, Sørlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature 2000;406:747-52.
13. van't Veer LJ, Dai H, van de Vijver MJ, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002;415:530-6.
14. Friedman LS, Ostermeyer EA, Szabo CI, et al. Confirmation of BRCA1 by analysis of germline mutations linked to breast and ovarian cancer in ten families. Nat Genet 1994;8:399-404.
15. Monteiro AN. BRCA1: exploring the links to transcription. Trends Biochem Sci 2000;25:469-74.
16. Lane TF. BRCA1 and transcription. Cancer Biol Ther 2004;3:528-33.
17. Harkin DP, Bean JM, Miklos D, et al. Induction of GADD45 and JNK/SAPK-dependent apoptosis following inducible expression of BRCA1. Cell 1999;97:575-86.
18. MacLachlan TK, Somasundaram K, Sgagias M, et al. BRCA1 effects on the cell cycle and the DNA damage response are linked to altered gene expression. J Biol Chem 2000;275:2777-85.
19. Somasundaram K, Zhang H, Zeng YX, et al. Arrest of the cell cycle by the tumour-suppressor BRCA1 requires the CDK inhibitor p21WAF1/CiP1. Nature 1997;389:187-90.
20. Chen Y, Farmer AA, Chen CF, Jones DC, Chen PL, Lee WH. BRCA1 is a 220-kDa nuclear phosphoprotein that is expressed and phosphorylated in a cell cycle-dependent manner. Cancer Res 1996;56:3168-72.
21. Bork P, Hofmann K, Bucher P, Neuwald AF, Altschul SF, Koonin EV. A superfamily of conserved domains in DNA damage-responsive cell cycle check-point proteins. FASEB J 1997;11:68-76.
22. Wang Y, Cortez D, Yazdi P, Neff N, Elledge SJ, Qin J. BASC, a super complex of BRCA1-associated proteins involved in the recognition and repair of aberrant DNA structures. Genes Dev 2000;14:927-39.
23. Couch FJ, Weber BL. Mutations and polymorphisms in the familial early-onset breast cancer (BRCA1) gene. Breast Cancer Information Core. Hum Mutat 1996;8:8-18.
24. Ludwig T, Fisher P, Ganesan S, Efstratiadis A. Tumorigenesis in mice carrying a truncating Brca1 mutation. Genes Dev 2001;15:1188-93.
25. Baudi F, Quaresima B, Grandinetti C, et al. Evidence of a founder mutation of BRCA1 in a highly homogeneous population from southern Italy with breast/ovarian cancer. Human Mutation 2001;18:163-4.
26. Sasaki H, Yu CY, Dai M, et al. Elevated serum periostin levels in patients with bone metastases from breast but not lung cancer. Breast Cancer Res Treat 2003;77:245-52.
27. Quaresima B, Faniello MC, Baudi F, et al. Missense mutations of BRCA1 gene affect the binding with p53 both in vitro and in vivo. Oncol Rep 2006;16:811-5.
28. Tassone P, Tagliaferri P, Perricelli A, et al. BRCA1 expression modulates chemosensitivity of BRCA1-defective HCC1937 human breast cancer cells. Br J Cancer 2003;88:1285-91.
29. Wright GW, Simon RM. A random variance model for detection of differential gene expression in small microarray experiments. Bioinformatics 2003;19:2448-55.
30. Tibshirani R, Hastie T, Narasimhan B, Chu G. Diagnosis of multiple cancer types by shrunken centroids of gene expression. Proc Natl Acad Sci U S A 2002;99:6567-72.
31. Tusher VG, Tibshirani R, Chu G. Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci U S A 2001;98:5116-21.
32. Crugliano T, Quaresima B, Gaspari M, et al. Specific changes in the proteomic pattern produced by the BRCA1-1841Asn missense mutation. Int J Biochem Cell Biol 2007;39:220-6.
33. Quaresima B, Faniello MC, Baudi F, et al. Transcriptional regulation of the mismatch repair gene hMLH1. Gene 2001;275:261-5.
34. Hamelinck D, Zhou H, Li L, et al. Optimized normalization for antibody microarrays and application to serum-protein profiling. Mol Cell Proteomics 2005;6:773-84.
35. Horiuchi K, Amizuka N, Takeshita S, et al. Identification and characterization of a novel protein, periostin, with restricted expression to periosteum and periodontal ligament and increased expression by transforming growth factor beta. J Bone Miner Res 1999;14:1239-49.
36. Takeshita S, Kikuno R, Tezuka K, Amann E. Osteoblast specific factor 2: cloning of a putative bone adhesion protein with homology with the insect protein fasciclin I. Biochem J 1993;294:271-8.
37. Gillan L, Matei D, Fishman DA, Gerbin CS, Karlan BY, Chang DD. Periostin secreted by epithelial ovarian carcinoma is a ligand for α(V)β(3) and α(V)β(5) integrins and promotes cell motility. Cancer Res 2002;62:5358-64.
38. Ismail RS, Baldwin RL, Fang J, et al. Differential gene expression between normal and tumor-derived ovarian epithelial cells. Cancer Res 2000;60:6744-49.
39. Sasaki H, Dai M, Auclair D, et al. Serum level of the periostin, a homologue of an insect cell adhesion molecule, in thymoma patients. Cancer Lett 2001;172:37-42.
40. Sasaki H, Dai M, Auclair D, et al. Serum level of the periostin, a homologue of an insect cell adhesion molecule, as a prognostic marker in non-small cell lung carcinomas. Cancer 2001;92:843-8.
41. Shao R, Bao S, Bai X, et al. Acquired expression of periostin by human breast cancers promotes tumor angiogenesis through up-regulation of vascular endothelial growth factor receptor 2 expression. Mol Cell Biol 2004;24:3992-4003.
42. Liu T, Qian WJ, Gritsenko MA, et al. Human plasma N-glycoproteome analysis by immunoaffinity subtraction, hydrazide chemistry, and mass spectrometry. J Proteome Res 2005;4:2070-80.
43. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 1991;19:403-10.
44. Schena M, Shalon D, Davis RW, Brown PO. Quantitative monitoring of gene expression patterns with a complementary DNA microarray. Science 1995;270:467-70.
45. Lochter A, Werb Z, Bissell MJ. Transcriptional regulation of stromelysin-1 gene expression is altered during progression of mouse mammary epithelial cells from functionally normal to malignant. Matrix Biol 1999;18:455-67.
46. Vajkoczy P, Menger MD, Goldbrunner R, et al. Targeting angiogenesis inhibits tumor infiltration and expression of the pro-invasive protein SPARC. Int J Cancer 2000;87:261-8.
47. Erkan M, Kleeff J, Gorbachevski A, et al. Periostin creates a tumor-supportive microenvironment in the pancreas by sustaining fibrogenic stellate cell activity. Gastroenterology 2007;132:1447-64.
48. Siriwardena BS, Kudo Y, Ogawa I, et al. Periostin is frequently overexpressed and enhances invasion and angiogenesis in oral cancer. Br J Cancer 2006;95:1396-403.
49. Baril P, Gangeswaran R, Mahon PC, et al. Periostin promotes invasiveness and resistance of pancreatic cancer cells to hypoxia-induced cell death: role of the β4 integrin and the PI3K pathway. Oncogene 2007;26:2082-94.
50. Kudo Y, Ogawa I, Kitajima S, et al. Periostin promotes invasion and anchorage-independent growth in the metastatic process of head and neck cancer. Cancer Res 2006;66:6928-35.
51. Lindner V, Wang Q, Conley BA, Friesel RE, Vary CP. Vascular injury induces expression of periostin: implications for vascular cell differentiation and migration. Arterioscler Thromb Vasc Biol 2005;25:77-83.
52. Sasaki H, Sato Y, Kondo S, et al. Expression of the periostin mRNA level in neuroblastoma. J Pediatr Surg 2002;37:1293-97.
53. Kudo Y, Siriwardena BS, Hatano H, Ogawa I, Takata T. Periostin: novel diagnostic and therapeutic target for cancer. Histol Histopathol 2007;22:1167-74.